Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. - Wikidata - wikimedia - TriplyDB

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

http://www.wikidata.org/entity/Q37252270

about

Functionally defective germline variants of sialic acid acetylesterase in autoimmunity Genetic and epigenetic alterations in pancreatic carcinogenesis The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Systemic therapies for pancreatic cancer--the role of pharmacogenetics Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction Drosophila cbl is essential for control of cell death and cell differentiation during eye development Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer Pancreatic cancer.Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis.Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.Understanding resistance to EGFR inhibitors-impact on future treatment strategies Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis Genetic variants in epidermal growth factor receptor pathway genes and risk of esophageal squamous cell carcinoma and gastric cancer in a Chinese population.A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.A growing family: adding mutated Erbb4 as a novel cancer target High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer HER family inhibitors in pancreatic cancer: current status and future directions.Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.Emerging drugs for the treatment of pancreatic cancer.Molecular targeted therapies for pancreatic cancer.Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Epidermal growth factor receptor in pancreatic cancer.The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.Somatic pharmacogenomics in cancer.The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.ErbB receptors in the biology and pathology of the aerodigestive tract

P2860

Q24322817-DB2858A5-8127-49FD-B9A2-A8B391EBEB72 Q24598655-EE69F482-A654-4960-A3C7-789DAB38BFAF Q24649549-53EA0C09-608A-4B6D-AEC3-BFB8A9C5A236 Q27021716-5E19DBEB-8948-42C8-A450-55CB4A17F3DA Q27026253-C27B8759-8333-415A-826D-7E904F271444 Q28471948-ADFAA5B5-6804-4A37-97AB-D27C82AC7A16 Q30436049-81A4EE98-D09F-4059-A8CA-601742E40D35 Q30490247-69B77B9F-3FDC-49D7-A74E-FEFAC017051A Q33610075-ABA8D565-B75F-4319-93A5-C55E79F346C2 Q33932460-2571B4D2-471D-4EA8-8269-B57CD113B2F8 Q33947959-A0634C8A-A756-4411-9895-77342765A8DA Q34088424-288B4DB4-EE22-47C5-BC4A-80D43B7AF22F Q34496697-9DDB35B1-09F9-4AA8-9E17-1E0AEA2B07B0 Q34497010-06BAF516-26FA-48FA-8C36-7B8461F27ACD Q34597750-BCD688A4-E9F5-447A-98E4-E5635C2897A6 Q34852402-553DA889-8FDA-4413-AF89-A64BE86A6C65 Q35050662-5A472BCA-F434-4709-A3B4-813E9056EDEB Q35208151-A6DF449B-DB8A-41EE-9F5C-7C7E3B193A02 Q36014381-2E8B4397-91C0-4929-A001-6DD8F46F02D9 Q36062442-D40F6536-9649-4D4B-8A76-6B65907612A4 Q36210986-8D20D7E6-3CAF-47A8-88C3-647D040D7474 Q36228534-66FBD326-AA74-4405-B5CD-EF23ACAB46E9 Q36410371-7F1ACAB5-3DE6-40CB-8B68-3C9EED50E0FF Q36475391-0CC75A3A-35A4-4CA1-A660-29E18EFEC8B0 Q36526959-460C9E8B-8B6E-4E3F-91D4-5BB2531CA6A2 Q36582547-4C127097-82C9-4A67-8398-06EC2CFB9C7E Q36611021-56832A3B-3917-48D0-BA1E-1FA8F09B1F78 Q36669662-33F0AFB8-7348-450E-9630-AFD88739C070 Q36714384-893FA885-97B7-435B-8C13-260748783542 Q36734936-845258DC-59DC-4D29-ACF3-AE1A2A0DCA0C Q36824808-C36055A8-AA6A-4EFE-9318-4F2EADA8A1E6 Q36866617-597AF6F0-27E0-43FC-9B60-9F69444783FD Q36944441-1FAA0B19-4EB2-4B5E-90D5-0BBC6E19A615 Q37004639-68BDA8E5-CF48-4F4D-AFC9-1337EBDFC67E Q37077239-42622531-439C-4A5C-A5EC-BA0A3ECB3B91 Q37132640-BA7ACEAB-1F8B-4605-8555-C88D2A55E2DC Q37156381-3FCF0D34-ABB9-445F-8322-A9347AA4BBB0 Q37235024-FD1ECBB7-ABBB-49D6-A7C9-E5B0D2907D76 Q37235527-46F77142-7F5C-4C40-A615-F62ECEB8F703 Q37263452-045422F0-D676-4231-B445-0C2201DF5C23

P2860

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.

http://www.wikidata.org/entity/Q37252270

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2006

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@en

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@nl

type

label

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@en

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@nl

prefLabel

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@en

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@nl

P1433

Q37252270-10400B91-5EF2-4A1E-A789-87A27E83F2C7

P1476

Q37252270-85334A98-B3D9-486E-BCED-27499D5916FF

P2093

Q37252270-15987D18-A4C4-49C3-8D19-5DAC22CA1F27

Q37252270-18857475-9BA7-4DC4-9958-1617E1591C5D

Q37252270-2BE1B4DF-C811-4FC6-88B0-0757E8554834

Q37252270-2EF0DBBD-D7DB-4F14-9C21-9F881D7EE64D

Q37252270-4C8C8FD9-46C9-425B-87D4-5AE230C8B778

Q37252270-5DB755D7-8C0F-48E3-97AF-A6738F46F61A

Q37252270-5F8D137D-ACF4-457E-813D-56A2B10FD381

Q37252270-8160070B-63E7-4D18-8D7D-BA10F8F10573

Q37252270-9B0BA6B6-C46F-4A44-BF35-96D6043C7A33

Q37252270-A17E1190-B293-4E33-AB47-F04910537CFB

P2860

Q37252270-006ACD9B-5F5E-4440-BFD1-9A4160A7F2E8

Q37252270-08EBA3C8-E32C-48D1-A730-62D431CFA379

Q37252270-0D1E7645-D318-4567-9414-F2AFC0950C00

Q37252270-0E93939A-0FF8-4E8D-A56B-239C68CDB10B

Q37252270-1406D344-4F0E-4D5E-AABD-83A9E02A7378

Q37252270-1E377D7C-EBF2-4CCE-BC58-C17BBD266CA5

Q37252270-21D676CF-F8D5-4477-9CDB-657DEB92F6D5

Q37252270-305A87D5-157C-4E80-A321-82DC0D76DB05

Q37252270-31FC62E4-2275-4F0B-879F-2BA419572809

Q37252270-37736972-2A20-4385-9297-4D7F99747315

P304

Q37252270-6AE8B516-C5F7-43C1-BB60-F9748032A47B

P31

Q37252270-A4E7A50E-22DB-41DC-8754-2FDB544AC369

P356

Q37252270-19904390-430B-4A59-BAC7-E0AA2F917C6B

P407

Q37252270-D732DF2D-F523-46E4-9F0D-D7996B153DD6

P433

Q37252270-B57ED448-182B-42DD-BB0D-4EFD56611A33

P478

Q37252270-7CAA666D-5501-4831-8BCE-0484615B6738

P50

Q37252270-2E94235F-EC18-4429-B86C-6B33B6BF366F

P577

Q37252270-8118B214-FCE3-4F15-9FAC-CEDF9A798F20

P698

Q37252270-56A04E99-0566-4EEC-91C6-B3BD56B86D0D

P921

Q37252270-57770CA6-F077-44D1-8949-471C2B8AFC62

P932

Q37252270-4C79AD88-FF99-4EE7-B7E4-B1984862A7AD

P356

1078-0432.CCR-06-0189

P1433

Clinical Cancer Research

P1476

Epidermal growth factor recept ...... nd pancreatic adenocarcinomas.

@en

P2093

Beth Muir

http://www.w3.org/2001/XMLSchema#string

Brian W Brannigan

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

Daphne W Bell

http://www.w3.org/2001/XMLSchema#string

David Ferry

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

David R Driscoll

http://www.w3.org/2001/XMLSchema#string

Dennis C Sgroi

http://www.w3.org/2001/XMLSchema#string

Eunice L Kwak

http://www.w3.org/2001/XMLSchema#string

Gregory Y Lauwers

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Erlotinib in previously treated non-small-cell lung cancer

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P304

4283-4287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-0189

http://www.w3.org/2001/XMLSchema#string

P407

P433

14 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16857803

http://www.w3.org/2001/XMLSchema#string

P921

P932

3807136

http://www.w3.org/2001/XMLSchema#string